Dr. rer. nat. Simon Völkl

Department of Medicine 5 – Haematology and Oncology

CD19-targeted CAR T cells in refractory antisynthetase syndrome (2023) Müller F, Böltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, et al. Journal article Accumulation of T-cell-suppressive PD-L1 high extracellular vesicles is associated with GvHD and might impact GvL efficacy (2023) Baur R, Karl F, Böttcher-Loschinski R, Stoll A, Völkl S, Gießl A, Flamann C, et al. Journal article Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. (2023) Bergmann C, Müller F, Distler J, Györfi AH, Völkl S, Aigner M, Kretschmann S, et al. Journal article, Letter Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma (2023) Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, et al. Journal article Tumor microenvironment-dependent epigenetic imprinting in the vasculature predicts colon cancer outcome (2023) Naschberger E, Fuchs M, Dickel N, Kunz M, Popp B, Anchang CG, Demmler R, et al. Journal article Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL (2023) Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, et al. Journal article Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. (2023) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article, Erratum The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome (2022) Richter S, Böttcher M, Mackensen A, Ullrich E, Jacobs B, Mougiakakos D, Völkl S Journal article Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution